US20260315614
2026-10-15
Human necessities
A61K47/6811
A novel series of GLP1R-GIPR dual agonist peptides and their conjugates with anti-myostatin antibodies are introduced, aimed at treating diabetes, obesity, and related metabolic disorders. These conjugates target the glucagon-like peptide-1 receptor (GLP1R), glucose-dependent insulinotropic polypeptide receptor (GIPR), and growth and differentiation factor-8 (GDF8) pathways. The approach focuses on reducing body weight and fat mass while preserving or enhancing muscle mass.
The focus is on the development of protein-ligand conjugates, specifically GLP1R and GIPR dual agonists linked with GDF8 antibodies. These conjugates are designed to treat conditions associated with GDF8, GLP1R, and GIPR. The singular molecular entity effectively engages all three targets, promoting weight loss while maintaining lean body mass, addressing a critical need in obesity and diabetes management.
Obesity and type 2 diabetes are significant global health challenges, with obesity affecting over a third of the world's population. In the U.S., obesity-related medical costs are a substantial burden. Current GLP1R agonists, while effective in weight reduction, often lead to lean muscle loss. There is a pressing need for therapies that manage obesity and diabetes more effectively, preserving lean mass while reducing body weight.
The innovation involves a conjugate composed of an antigen-binding protein (ABP) and a GLP1R-GIPR dual agonist, connected via a linker. The ABP is typically an antibody targeting and inhibiting GDF8 activity. This conjugate aims to provide obesity management with minimal lean mass loss, improving clinical outcomes. The dual agonist and antibody conjugates are designed to engage specific sequences and regions, enhancing therapeutic efficacy.
By combining the effects of GLP1R and GIPR agonists with GDF8 inhibition, the conjugates offer a comprehensive approach to treating obesity and diabetes. The targeted mechanism not only aids in weight reduction but also supports muscle mass maintenance, addressing a significant gap in current treatment options. This approach could lead to more effective management of metabolic disorders, with a better side effect profile.